Laurie Vertuccio has joined Profound Medical (NASDAQ:PROF; TSX:PRN) as Vice President of Global Marketing.
The TULSA procedure, performed using Profound’s TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer.
Ms. Vertuccio joins Profound from a larger company focused on one segment of the prostate disease space, PROCEPT BioRobotics (NASDAQ:PRCT). PROCEPT is commercializing its Aquablation technology for the treatment of BPH only.
In a LinkedIn post announcing her move, Ms. Vertuccio said, “Prostate cancer is a cause deeply personal to me—my immediate family has been affected, and I witnessed firsthand how my father’s quality of life was impacted following a radical prostatectomy. It’s time we offer men a better treatment option—one that doesn’t force them to choose between being cancer-free and preserving their quality of life.”
“I’m proud to serve in this role for my father, my husband, my son, and for all the men impacted by prostate cancer. Together, we can make a profound difference,” she added.
TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report a quick recovery to their normal routine.
